Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYQVIA ramp-up vs no ramp-up in healthy adults
NCT04578535Phase 1Completed
- Sponsor
- Takeda
- Start
- Oct 2020
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Human normal immunoglobulin G in primary immunodeficiency (PI) (6 arms), sponsored by Takeda. Primary endpoint: Number of Participants Who Tolerated All Initiated HYQVIA Infusion at Week 9. Started Oct 2020; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT04578535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04578535.